PMID- 37314204
OWN - NLM
STAT- MEDLINE
DCOM- 20230814
LR  - 20230814
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 153
IP  - 7
DP  - 2023 Oct 1
TI  - The trichotomy of HER2 expression confers new insights into the understanding and 
      managing for breast cancer stratified by HER2 status.
PG  - 1324-1336
LID - 10.1002/ijc.34570 [doi]
AB  - Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor 
      that plays a carcinogenic role in breast cancer (BC) through gene amplification, 
      mutation, or overexpression. Traditional methods of HER2 detection were divided 
      into positive (immunohistochemistry (IHC) 3+/fluorescence in situ hybridization 
      (FISH) amplification) and negative (IHC 2+/FISH-, IHC 1+, IHC 0) according to the 
      dichotomy method. Anti-HER2-targeted therapies, such as trastuzumab and 
      pertuzumab, have significantly improved the prognosis of HER2-positive patients. 
      However, up to 75% to 85% of patients remain HER2-negative. In recent years, with 
      the rapid development of molecular biology, gene detection technology, targeted 
      therapy, and immunotherapy, researchers have actively explored the 
      clinicopathological characteristics, molecular biological characteristics, 
      treatment methods, and HER2 detection methods of HER2-low/zero breast cancer. 
      With the clinical efficacy of new anti-HER2 targeted drugs, accurate 
      classification of breast cancer is very important for the treatment choice. 
      Therefore, the following review summarizes the necessity of developing HER2 
      detection methods, and the clinicopathological and drug treatment characteristics 
      of patients with HER2-low/zero, to light the dawn of the treatment of breast 
      cancer patients with HER2-low/zero expression.
CI  - (c) 2023 UICC.
FAU - Jiang, Mingxia
AU  - Jiang M
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Liu, Jiaxuan
AU  - Liu J
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Li, Qiao
AU  - Li Q
AUID- ORCID: 0000-0002-4547-1266
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Xu, Binghe
AU  - Xu B
AUID- ORCID: 0000-0003-4195-337X
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230614
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/genetics/therapy/metabolism
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Trastuzumab/therapeutic use
MH  - Prognosis
MH  - Treatment Outcome
MH  - Gene Amplification
OTO - NOTNLM
OT  - HER2-low expression
OT  - HER2-zero expression
OT  - IHC
OT  - breast cancer
OT  - therapy
EDAT- 2023/06/14 13:07
MHDA- 2023/08/14 06:42
CRDT- 2023/06/14 09:04
PHST- 2023/04/26 00:00 [revised]
PHST- 2023/01/20 00:00 [received]
PHST- 2023/04/28 00:00 [accepted]
PHST- 2023/08/14 06:42 [medline]
PHST- 2023/06/14 13:07 [pubmed]
PHST- 2023/06/14 09:04 [entrez]
AID - 10.1002/ijc.34570 [doi]
PST - ppublish
SO  - Int J Cancer. 2023 Oct 1;153(7):1324-1336. doi: 10.1002/ijc.34570. Epub 2023 Jun 
      14.